Clinical Trial Results:
A Phase 1b/2, Open-label, Multicenter Dose-ranging Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SRA737 in Combination With Niraparib in Subjects With Metastatic Castration-resistant Prostate Cancer
Summary
|
|
EudraCT number |
2017-004927-56 |
Trial protocol |
GB |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
11 Sep 2021
|
First version publication date |
11 Sep 2021
|
Other versions |
|
Summary report(s) |
SRA737-03 EudraCT Premature Termination |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.